Clinical trials: Chronic Obstructive Pulmonary Disease, Unspecified
- Condition Chronic Obstructive Pulmonary Disease, Unspecified
- Funder type Industry (pharma, biotech, devices)
BPCO
Effectiveness of the Telemonitoring Program for Patients With Chronic Obstructive Pulmonary Disease (COPD)
Telemonitoring systems have already demonstrated their ability to improve clinical follow-up and reduce healthcare resource utilization in patients with chronic respiratory failure treated with non-invasive ventilation (NIV)…
- Trial name
- EProTele (NCT07697105)
- Testing
- Patients included in the intervention group will receive medical telemonitoring using the HCAlert medical device.
- Volunteers
- 340 people
- Sponsor
- Hope Care, S.A
Pulmonary Disease, Chronic Obstructive
Comparative Study of Fluticasone Furoate(FF)/Umeclidinium Bromide (UMEC)/ Vilanterol (VI) Closed Therapy Versus FF/VI Plus UMEC Open Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
This multicenter study will be conducted to compare the effect of FF/UMEC/VI with FF/VI plus UMEC on lung function after 24 weeks of treatment.
- Trial name
- NCT02729051
- Testing
- FF/UMEC/VI, FF/VI, UMEC
- Where
- 127 sites in Argentina, Australia and 10 more
- Volunteers
- 1,055 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
The purpose of this study is to assess the effectiveness and safety of JNJ 49095397 in participants with symptomatic moderate to severe chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT01867762
- Testing
- JNJ 49095397
- Where
- 47 sites in United States, Belgium and 9 more
- Volunteers
- 211 people
- Sponsor
- Janssen Research & Development, LLC
COPD
Safety, Tolerability and Pharmacodynamics of QAX028 Compared to Open-label Tiotropium Bromide and Placebo in Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD) Patients.
This will be a single dose Proof-of-Concept study in mild-to-moderate COPD patients. The study will investigate the safety and tolerability of QAX028 as well as the bronchodilatory effects of QAX028 compared to tiotropium and…
- Trial name
- NCT00568503
- Testing
- QAX028, Tiotropium bromide
- Where
- Denmark
- Volunteers
- 29 people
- Sponsor
- Novartis
Chronic Obstructive Pulmonary Disease
A Study of CM512 in Subjects With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase II Study to Explore the Efficacy and Safety of CM512 Injection in Adults with Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT06980142
- Testing
- CM512
- Volunteers
- 204 people
- Sponsor
- Keymed Biosciences Co.Ltd
Chronic Obstructive Pulmonary Disease
Efficacy and Safety of Two Fixed Dose Combinations of Aclidinium Bromide With Formoterol Fumarate
The purpose of this multicenter, dose-ranging study is to compare two Fixed-Dose Combinations of aclidinium bromide and formoterol fumarate with placebo, aclidinium bromide and formoterol fumarate, all administered BID in…
- Trial name
- ALIGHT-COPD (NCT01078623)
- Testing
- Aclidinium 200 μg / formoterol 12 μg, Formoterol 12 μg, Aclidinium 200 μg
- Where
- 10 sites in Czechia, Romania
- Volunteers
- 176 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
A Crossover Study to Determine the Effect on Lung Function of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Tiotropium as an Active Control
The study compared the 24-hour spirometry profile of indacaterol with that of placebo and with tiotropium as an active control in patients with chronic obstructive pulmonary disease.
- Trial name
- NCT00615459
- Testing
- Indacaterol, Tiotropium
- Where
- 20 sites in Australia, Germany and 5 more
- Volunteers
- 169 people
- Sponsor
- Novartis
Pulmonary Disease, Chronic Obstructive
Ipratropium Bromide in Peri-Operative COPD
This is a randomized, double-blind, placebo-controlled, parallel-group, multi-centre trial.The trial aims to evaluate efficacy of nebulized ipratropium bromide in Chinese peri-operative patients with COPD under general…
- Trial name
- NCT01943552
- Testing
- ipratropium bromide
- Where
- 9 sites in China
- Volunteers
- 192 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
A Randomized Study to Evaluate the Effect of Reminder Notifications and Motivational/Adaptive Messaging on Treatment Adherence
This study was evaluating the effect of reminder notifications and motivational/adaptive messages on treatment adherence behavior in subjects with COPD.
- Trial name
- ADVICE (NCT03379233)
- Testing
- Concept2 inhaler, Concept2 inhaler with patient application
- Where
- 9 sites in Germany, Netherlands
- Volunteers
- 7 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
A Pilot Study of Danirixin for Disease Progression in Chronic Obstructive Pulmonary Disease (COPD)
This is a pilot study to investigate the effect of danirixin hydrobromide 35 milligram (mg) tablets on lung function and health related quality of life (HRQoL) in subjects with mild to moderate airflow obstruction and a…
- Trial name
- NCT03170232
- Testing
- Danirixin 35 mg tablets, Metered dose inhaler (MDI) sensor device, Rescue medication
- Where
- 11 sites in United States
- Volunteers
- 54 people
- Sponsor
- GlaxoSmithKline
Asthma-COPD Overlap Syndrome
A Non-interventional Study to Investigate the Current Situation of Asthma-COPD Overlap Syndrome in Patients Over Age 40 With Persistent Airflow Limitation in China
To investigate the distributions of the patients with ACOS, asthma and COPD over age 40 with chronic airflow limitation in China.
- Trial name
- NCT02600221
- Where
- 13 sites in China
- Volunteers
- 2,016 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.
The overall objective is to assess the effect of once daily tiotropium + olodaterol fixed dose combination compared to 5 µg tiotropium (both delivered with the Respimat® inhaler) on moderate to severe COPD exacerbation in…
- Trial name
- NCT02296138
- Testing
- olodaterol, tiotropium
- Where
- 818 sites in United States, Argentina and 49 more
- Volunteers
- 7,903 people
- Sponsor
- Boehringer Ingelheim
Healthy Volunteers, Chronic Obstructive Pulmonary Disease
Cardiac Safety of Indacaterol
This study compares the cardiac safety of inhaled indacaterol with that of placebo and oral moxifloxacin.
- Trial name
- NCT01263808
- Testing
- Indacaterol 150 µg, Indacaterol 300 µg, Indacaterol 600 µg
- Where
- United States
- Volunteers
- 404 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
COPD
A Safety, Tolerability and Efficacy Study in Chronic Obstructive Pulmonary Disease (COPD) Patients With QBM076.
This was a 2 Part study. Part 1 was a safety and tolerability study in GOLD I-III COPD patients. Part 2 was an efficacy study in GOLD I-III COPD patients.
- Trial name
- NCT01972776
- Testing
- QBM076
- Where
- 7 sites in United States, Germany and 2 more
- Volunteers
- 48 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Tiotropium Respimat Pharmacokinetic Study in COPD
The purpose of this study is compare the effect of different doses of tiotropium delivered by the HandiHaler and Respimat device on lung function.
- Trial name
- NCT01222533
- Testing
- Tiotropium medium, Tiotropium low, Tiotropium high
- Where
- 11 sites in Belgium, Denmark and 3 more
- Volunteers
- 154 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive, Pulmonary Fibrosis
Interferon-alpha Treatment of Chronic Cough in Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis
The purpose of this study is to determine whether lozenges containing interferon-alpha can reduce the frequency and severity of coughing in patients with chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary…
- Conditions
- Pulmonary Disease, Chronic Obstructive, Pulmonary Fibrosis, Cough
- Trial name
- NCT00690885
- Testing
- interferon-alpha lozenges
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
Pulmonary Disease, Chronic Obstructive
Randomized Study Evaluating the Effect of Danirixin on Neutrophil Extracellular Traps (NETs) in Chronic Obstructive Pulmonary Disease (COPD)
The inflammation associated with COPD is characterized by a prominent infiltration of neutrophils in lung tissue and airways. The CXC chemokine receptor type 2 (CXCR2) plays a pivotal role in neutrophil recruitment to the lungs…
- Trial name
- NCT03250689
- Testing
- Danirixin, Rescue medication, Inhaled COPD maintenance medication
- Where
- United Kingdom
- Volunteers
- 19 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Pilot Study Comparing Tiotropium (Spiriva) to Salmeterol (Serevent) Plus Fluticasone (Flixotide) in Chronic Obstructive Pulmonary Disease (COPD)
The primary objective of this study is to estimate the comparative bronchodilator effect size and variability for tiotropium (Spiriva, 18 µg q.d.) with the free combination of salmeterol (Serevent, 50 µg b.i.d.) and fluticasone…
- Trial name
- NCT00239499
- Testing
- Tiotropium, Salmeterol plus Fluticasone
- Where
- 12 sites in South Africa
- Volunteers
- 107 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
A Collection of Vital Status and Pulmonary Medication Usage Data for Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Withdrew Prematurely From Tiotropium Inhalation Solution Delivered by the Respimat Inhaler
The objectives were to collect information on vital status and pulmonary medication use at the predicted exit date for patients who participated in two one-year trials and withdrew prematurely.
- Trial name
- NCT02172560
- Testing
- Tiotropium
- Where
- 19 sites in Australia, New Zealand and 1 more
- Volunteers
- 441 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Study to Evaluate the Safety and Efficacy of Inhaled PT005 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to evaluate the safety and efficacy of inhaled PT005 compared to placebo and Formoterol Fumarate (Foradil Aerolizer) in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00880490
- Testing
- Inhaled PT005, Formoterol Fumarate 12 mcg (Foradil Aerolizer)
- Where
- 5 sites in Australia, New Zealand
- Volunteers
- 34 people
- Sponsor
- Pearl Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.